SK chemicals

The company's flagship medicine, presented as its first natural-product new drug; 2025 sales were KRW 59.5 billion, 12.2% of pharmaceutical revenue.

Low-dose triple-combination hypertension drug containing telmisartan 20 mg, amlodipine 2.5 mg and chlorthalidone 6.25 mg, each about half the standard dose; developed with Yuhan and launched in April 2026.

Copolyester brand with transparency, chemical resistance and processability, used in cosmetics packaging, household goods and appliances.

Copolyester ECOTRIA CLARO and PET resin SKYPET product lines; in May 2026 they received RecyClass Technology Approval in Europe confirming compatibility with existing PET recycling processes.

Subsidiary in vaccines, including the influenza vaccine SKYCellflu, and contract development and manufacturing; it is included in SK chemicals' consolidated results.

Signed an MOU with J2H Biotech to explore joint development of treatments for MASH and idiopathic pulmonary fibrosis (IPF).

Launched Telamclo, a low-dose triple-combination hypertension drug co-developed with Yuhan, in Korea.

Announced that seven plastic materials, including ECOTRIA CLARO and SKYPET, received RecyClass Technology Approval in Europe for PET recycling compatibility.

Reported Q2 2026 standalone revenue of KRW 479.1 billion and operating profit of KRW 31.9 billion, driven by copolyester sales and key pharmaceutical products.